Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Anticancer Res ; 36(4): 2019-26, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27069196

ABSTRACT

BACKGROUND: Detection of circulating tumor cells (CTC) in patients with castration-resistant prostate cancer (CRPC) may improve the estimate of chemotherapy response. We evaluated the AdnaTest® system in patients receiving docetaxel. PATIENTS AND METHODS: CTC analysis was carried out in 37 patients by immunomagnetic separation. Correlation between serum prostate-specific antigen (sPSA) change and CTC presence and the influence of each parameter on the overall survival (OS) were evaluated. RESULTS: We detected CTCs in 32 and 16 patients before and after three docetaxel cycles, respectively. The sPSA level correlated with CTC positivity during docetaxel therapy (p=0.0031). The longest OS was in patients negative for CTCs in both samples (p=0.0228). Change in sPSA levels was associated with treatment response (p=0.033). CONCLUSION: We detected CTCs in a considerable number of patients with CRPC. The absolute change of sPSA level correlated with OS. CTC presence during docetaxel therapy was associated with shorter OS.


Subject(s)
Neoplastic Cells, Circulating , Prostatic Neoplasms, Castration-Resistant/blood , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Docetaxel , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Prognosis , Prostate-Specific Antigen/blood , Prostatic Neoplasms, Castration-Resistant/pathology , Reverse Transcriptase Polymerase Chain Reaction , Taxoids/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...